Study of YK012 in Primary Membranous Nephropathy
NCT06982729
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Membranous Nephropathy
Interventions
DRUG:
YK012
Sponsor
Excyte Biopharma Ltd